Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. The company highlights disciplined capital allocation and maintains a healthy balance sheet. Expansion projects like Guwahati, Mumbai, South Delhi, Pitampura, and others are ongoing, with construction timelines around 3 to 4 years, but no specific mention of fundraising plans related to these. The company seems focused on steady growth and operational ramp-up without indicating immediate need for additional funds via debt or equity. No direct guidance or announcements regarding

Any current/future capex/capital investment/strategic investment?

Guwahati Project: Completed acquisition of 3.5-acre land (~INR 600 million); Bhoomi Pujan done on October 31, 2025; construction commencement underway; expected 3-4 years to complete. Mumbai, Oshiwara Project: Received approval for increased FSI, expanding bed capacity from 500 to 750; Board approved new project cost of INR 15,300 million including land, construction, medical equipment, and INR 850 million for staff residential apartments; construction to start soon. South Delhi & Pitampura Projects: Digging started in South Delhi; Pitampura plans submitted for approval and construction to c

Future growth expectations in sales/revenue/volumes?

Developing hospitals (Lucknow, Patna, Noida) continue strong double-digit growth; revenue up ~30% YoY including Noida. Lucknow hospital showing 30% inpatient volume growth, occupancy ~67%, driven by added clinical talent and specialties. Ranchi facility expanding with new specialties and Oncology services planned; volumes growing ~15% YoY. Noida hospital operational since Sept 2025, early contribution noted; insurance empanelments expected soon to accelerate growth. Additional beds opened in Patna and Lucknow; more bed additions planned, supporting volume growth without necessarily requiring n

Future growth expectations in earnings/operating earnings/profits/EPS?

Management is optimistic about future growth, expecting steady ramp-up and improved performance in developing hospitals like Noida, Lucknow, Patna, and Ranchi over the next 12-18 months. New facilities (e.g., Ranchi expansion with 110 beds, Lucknow additions) are expected to gradually improve EBITDA margins as they stabilize. Mature hospitals showing modest EBITDA growth (~2% YoY); expects further margin improvement as additional manpower cost normalizes. Noida operational losses (~INR 20 crore EBITDA loss currently) expected to reduce as the hospital scales up, but no specific timeline or num

IN US

Sale is live|00:00:00left today

Global Health LtdQ3 FY25Healthcare Services

Global Health Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,312P/E: 60.0Market Cap: ₹33.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Developing hospitals (Lucknow, Patna, Noida) continue strong double-digit growth; revenue up ~30% YoY including Noida.
→Lucknow hospital showing 30% inpatient volume growth, occupancy ~67%, driven by added clinical talent and specialties.
→Ranchi facility expanding with new specialties and Oncology services planned; volumes growing ~15% YoY.
→Noida hospital operational since Sept 2025, early contribution noted; insurance empanelments expected soon to accelerate growth.
→Additional beds opened in Patna and Lucknow; more bed additions planned, supporting volume growth without necessarily requiring new hospitals.
→New projects in Guwahati, Mumbai (Oshiwara), South Delhi, and Pitampura progressing; expected commissioning ~3-4 years out.
→Growth drivers include bed expansion, specialist additions, and procedural complexity (e.g., robotic surgeries).
→International patient revenue up 49% YoY, indicating growth potential from overseas market.

Margin guidance

Category 3

→Management is optimistic about future growth, expecting steady ramp-up and improved performance in developing hospitals like Noida, Lucknow, Patna, and Ranchi over the next 12-18 months.
→New facilities (e.g., Ranchi expansion with 110 beds, Lucknow additions) are expected to gradually improve EBITDA margins as they stabilize.
→Mature hospitals showing modest EBITDA growth (~2% YoY); expects further margin improvement as additional manpower cost normalizes.
→Noida operational losses (~INR 20 crore EBITDA loss currently) expected to reduce as the hospital scales up, but no specific timeline or numbers given.
→ARPOB (average revenue per occupied bed) expected to stay strong with specialty mix optimization and growing complex care, especially in developing hospitals.
→New projects (Mumbai, Guwahati, South Delhi, Pitampura) are 3-4 years away, anticipated to contribute to growth beyond FY27.
→Conservative pricing approach maintained, with selective modest price increases; Patna price unchanged due to market strategy.
→Overall outlook reflects confidence in sustained volume growth, margin improvement, and disciplined capital allocation.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
→The company highlights disciplined capital allocation and maintains a healthy balance sheet.
→Expansion projects like Guwahati, Mumbai, South Delhi, Pitampura, and others are ongoing, with construction timelines around 3 to 4 years, but no specific mention of fundraising plans related to these.
→The company seems focused on steady growth and operational ramp-up without indicating immediate need for additional funds via debt or equity.
→No direct guidance or announcements regarding fundraising were made during the Q2 FY26 earnings call.

Order book

The provided transcript does not contain specific details about the current or expected order book or pending orders for Global Health Limited – Medanta. The discussion primarily focuses on hospital operations, bed expansions, revenue growth, EBITDA margins, insurance empanelments, and ongoing construction projects. Key points relevant to projects include: - Ongoing projects at South Delhi and Pitampura have commenced or are awaiting approvals; construction to follow. - Mumbai project now approved for 750 beds with construction approvals in progress. - Guwahati project land possession and Bhoomi Pujan completed; design work underway. - Typical hospital construction timeline is 3 to 4 years. - No explicit financial order book or specific pending order figures disclosed. For precise order book or pending orders data, please refer to detailed financial disclosures or investor communications beyond this transcript.

Capex plans

Yes

→Guwahati Project: Completed acquisition of 3.5-acre land (~INR 600 million); Bhoomi Pujan done on October 31, 2025; construction commencement underway; expected 3-4 years to complete.
→Mumbai, Oshiwara Project: Received approval for increased FSI, expanding bed capacity from 500 to 750; Board approved new project cost of INR 15,300 million including land, construction, medical equipment, and INR 850 million for staff residential apartments; construction to start soon.
→South Delhi & Pitampura Projects: Digging started in South Delhi; Pitampura plans submitted for approval and construction to commence post-approval; timeline also expected around 3-4 years.
→Ranchi Expansion: Commissioned 110 new beds; plans to add Oncology services and optimize specialty mix.
→Noida Hospital: Operational since September 2025; ongoing ramp-up and investments expected.
→Overall, multiple projects underway with 3-4 year build-out timelines and continued capital allocation focused on growth and strategic expansion.

How does Global Health Ltd rank vs peers in Healthcare Services?

Pro feature

1Global Health Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Global Health Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio